Inoviq Ltd · ASX:IIQ
Inoviq — Corporate Update (July 2026)
27 slides from Inoviq's corporate update, Jul 14, 2026
Slide 1: INOVIQ Ltd EXO-OC Test Investor Webinar
INOVIQ Ltd Next-generation cancer diagnostics and therapeutics EXO-OC Test Investor Webinar 14 July 2026 ASX: IIQ
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by INOVIQ Limited (“INOVIQ” or the “Company”) Actual results, performance or achievements could be significantly different from those based on information available to it as at the date of this presentation. This presentation expressed in, or implied by
Slide 3: Agenda
Agenda Retrospective clinical study outcomes p6 EXO-OC test and algorithm p20 refinement Ongoing development and p21 commercialisation plans Summary and Q&A p22 3
Slide 4: Key Operational Q&As
Key Operational Q&As Why weren’t the •All samples were sourced against predefined criteria, inspected on receipt in accordance with INOVIQ QC procedures and then stored for later sample processing and analysis in randomised batches under the HREC-approved Study Protocol. The provider-related sample
Slide 5: Key Governance Q&As
Key Governance Q&As What was the Board •The study was managed under INOVIQ’s established product development and governance processes including HREC-approved study protocols, structured project management and reporting processes, regular risk and progress reviews, and independent data analysis. Upon
Slide 6: OC2200 Study Review
OC2200 Study Review 4 “ SS ras : _ ise ST 4 o =INOVIQ
Slide 7: Biomarker Development | Discovery to commercialisation
Biomarker Development| Discovery to commercialisation CLIA Lab LDT Translation to CLIA Lab as an LDT we are here OC2200 OC500 OC97 UQ studies 7 Source: Adapted from Roche corporate presentation “Roche Diagnostics Driving Personalized Healthcare” April 2008
Slide 8: EXO-OC | Ovarian Cancer Screening Test (OC500 Study)
EXO-OC | Ovarian Cancer Screening Test (OC500 Study) Exosome-based blood test in development for early detection of Percent of Samples Correctly Identified by EXO-OC ovarian cancer in asymptomatic average-risk women • EXO-OC combines multiple exosomal miRNA + CA125 biomarkers in a machine learning (
Slide 9: EXO-OC | OC detection enabled by exosomal biomarkers, multiomic signals + AI/ML
EXO-OC | OC detection enabled by exosomal biomarkers, multiomic signals + AI/ML Assay Format Lab Workflow 1. EVs captured from plasma using EXO-NET® immuno-affinity beads with capture antibodies targeting exosome-associated surface markers 2. 6 exosomal miRNAs biomarkers are extracted and their abun
Slide 10: Design control for diagnostics | a hypothetical
Design control for diagnostics| an hypothetical DESIGN CONTROL GUIDANCE FOR MEDICAL DEVICE MANUFACTURERS Guidance relates to FDA 21 CFR 820.30 and Sub-clause 4.4 of ISO 9001 Clinical need: an accurate blood Design control test for early-stage ovarian cancer a systematic process ensuring with high sp
Slide 11: EXO-OC | Diagnostic development path
EXO-OC | Diagnostic development path LDT Development IVD Development OC500 OC2200 2025 2026 Biomarker Assay Analytical Clinical Marketing Clinical Utility Adoption Qualification Development Verification Validation Approval •Select markers •Design assay •Characterise test •Validate •Pivotal •Regulato
Slide 12: OC2200 | Biobank sample acquisition & analysis timeline
OC2200| Biobank sample acquisition & analysis timeline Samples rejected: Sample analysis Samples to be storage >5yrs completed 15 Jun Planned biobank <250 ul volume EXO-NET® Last samples transferred, Sample clinical & Additional acquisition by ASX pending sourcing from sample Sample analysis receive
Slide 13: Sample journey | Pre-Analytical factors impacting sample quality
Sample journey| Pre-Analytical factors impacting sample quality The Sample Journey 1 2 What Can Go Wrong IIQ Criteria for Biobanked Samples IIQ QC Steps for Prospective Samples In blood-based biomarker tests, including exosome-based tests, sample collection, handling and storage can impact test perf
Slide 14: OC2200 | Sample requirements & inclusion criteria provided to Biorepositories
OC2200| Sample requirements & inclusion criteria provided to Biorepositories Sample Requirements Clinical Criteria • Female donors aged 40-75 years collected under appropriate Inclusion IRB/HREC protocols and appropriate consent • Healthy controls • De-identified plasma and metadata supplied for eac
Slide 15: INOVIQ internal batch receipt and QC measures
INOVIQ internal batch receipt and QC measures Sample receipt and manifest QC Whole process & miRNA controls Precision checks RT-qPCR • Inspect container, dry ice status, • QC – WPC pooled human plasma • Duplicate samples included for and shipment temperature logs standard precision. • Reconcile IDs
Slide 16: Quality Management Systems control over Pre-Analytical factors
Quality Management Systems control over Pre-Analytical factors Clinical Setting, Multi-site Prospective or Multi-provider, Retrospective Study Single-provider Retrospective Study (OC500*) (OC2200*) blood collection sites blood collection sites processing storage transportation processing storage acc
Slide 17: Biomarker data | Consistent with degradation and provider-specific Pre-Analytical factors
Biomarker data| Consistent with degradation and provider-specific Pre-Analytical factors CA125 Protein Biomarker By Clinical Group miRNA Biomarkers in OC Samples By Biorepository Key finding 1: CA125 lower in OC2200 cancer Key finding 2: miRNA levels vary by biorepository samples, consistent with pr
Slide 18: Key Findings and Recommendations
Key Findings and Recommendations Findings Recommendations 1. CA125 protein varies x biorepository and is less than in OC500 • Complete technical review to inform further validation studies samples • Ongoing refinement of biomarkers and algorithm 2. miRNA varies x biorepository and is less than in OC
Slide 19: Next Steps
Next Steps 19
Slide 20: EXO-OC | Iterative model development to improve performance and expand clinical uses
EXO-OC | Iterative model development to improve performance and expand clinical uses Model 1 – Screening, average-risk asymptomatic Model 2 – Early detection, high-risk Designed to meet screening performance criteria for general population, Tuned to improve sensitivity across all stages to meet the
Slide 21: EXO-OC | Clinical and regulatory strategy
EXO-OC | Clinical and regulatory strategy Clinical validation studies to evaluate performance of EXO-OC for early OC detection • Objective: Evaluate EXO-OC in healthy controls + benign Dual commercialisation paths compared to cancer across both average and high-risk groups • Study design: retrospect
Slide 22: Summary and Q&A
Summary and Q&A es “S =INOVIQ
Slide 23: EXO-OC | LDT-to-IVD commercialisation strategy
EXO-OC | LDT-to-IVD commercialisation strategy Dual-path commercialisation strategy to maximise speed, access and value for patients, clinicians & investors Laboratory Developed Test In Vitro Diagnostic (LDT) (IVD) Laboratory partner Large diagnostics company Partner to offer testing service via for
Slide 24: EXO-OC | Commercial opportunities for early detection of Ovarian Cancer
EXO-OC | Commercial opportunities for early detection of Ovarian Cancer IN VITRO DIAGNOSTIC (IVD) LABORATORY-DEVELOPED TEST (LDT) Screening in Asymptomatic, Average-risk Women Early Detection in High-risk Women Market Eligible Population Screening Addressable Targeting same cohort of (45-74yo) 1 Par
Slide 25: IIQ pipeline | Multi-product exosome-based diagnostics & therapeutics portfolio
IIQ pipeline| Multi-product exosome-based diagnostics & therapeutics portfolio INOVIQ is developing next-generation exosome-based diagnostics and therapeutics that transform cancer care Our strategy is to provide integrated diagnostic and therapeutic solutions that enable earlier detection and more
Slide 26: Summary | Focus remains on progressing our high-value exosome pipeline
Summary| Focus remains on progressing our high-value exosome pipeline Exosome Critical unmet Early detection leader need for OC saves lives screening Priorities 1. Complete EXO-OC development & validation Leading exosome company Clinical-stage EXO-OC test Early detection of in case-control and high-
Slide 27: Q&A
Q&A Dr Leearne Hinch BVMS MBA Dr Rebecca Lim PhD Dr Emma Ball PhD MBA GAICD Chief Executive Officer Chief Scientific Officer Chief Commercial Officer e. lhinch@inoviq.com e. rlim@inoviq.com e. eball@inoviq.com Prof Gregory Rice PhD MHA Mark Edwards BAcc CA Founding Scientist & Advisor CFO & Company